comparemela.com

Graeme Meintjies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

PROFILE | What happened to HIV activist Zackie Achmat?

Zackie Achmat was one of the most vociferous voices against former president Thabo Mbeki's HIV denialism in the late 1990s and early 2000s. He now lives in downtown Cape Town and fights state capture — and broken trains, writes Sean Christie.

Whatever happened to HIV/Aids activist Zackie Achmat?

Zackie Achmat’s voice was one of the loudest when it came to protesting against former president Thabo Mbeki’s Aids denialism in the late 1990s and early 2000s. He now lives in downtown Cape Town and fights State Capture and broken trains.

SA universities make breakthrough with possible new Covid-19 vaccine

UCT trials next-gen Covid-19 vaccine to beat all current and future variants

UCT trials next-gen Covid-19 vaccine to beat all current and future variants 16 February 2021 11:43 AM Share This: The vaccine is developed by ImmunityBio, headed by South African billionaire Patrick Soon-Shiong (aka world s richest doctor ). RELATED: “Spike protein is mutation-prone,” says Professor Graeme Meintjies of the Department of Medicine at UCT. “The nucleocapsid protein [targeted by this new vaccine candidate] appears to be much more stable over time and therefore has a lower risk of developing mutations that could risk vaccine failure.” The next-generation vaccine is developed by ImmunityBio, headed by © goodluz/123rf.com “Our Covid-19 vaccine candidate could solve the growing problem of new variants of the virus that have begun to appear, said Soon-Shiong.

New 2nd generation vaccine includes 2 Covid proteins for broader immune response

New 2nd generation vaccine includes 2 Covid proteins for broader immune response 19 February 2021 5:48 PM Share This: UCT is working with US scientists to target the spiked protein plus the nucleocapsid protein, the protein found inside the virus. University of Cape Town (UCT) researchers are expected to start a phase one clinical trial of the Covid-19 vaccine candidate, hAd5 T-cell, later this month explains John Maytham. Professor Graeme Meintjes of the Department of Medicine at UCT and a co-investigator on the trial talks to John about the research. Meintjies explains what makes this vaccine different from others such as the Johnson&Johnson, AstraZeneca, and others that have come through clinical trials and are now being rolled out across the world.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.